pp-124 Tablets
Dossier type
CTD
Dossier status
Under development
Country of origin
China
GMP approvals
China
Comments
Indication: Moderate-to-severe acne vulgaris
Clinical stage: Phase 3 — ex-Greater China
Modality: Small molecule
Mechanism / Target: Fatty acid synthase (FASN) inhibitor — reduces de novo lipogenesis in sebocytes, decreasing sebum production and Cutibacterium acnes substrate
Route / form: Oral tablet (once daily)
Differentiation: First FASN inhibitor in acne Phase 3; targets root cause (sebum overproduction) vs symptomatic antibiotics/retinoids; oral once-daily
Manufacturer #39161
Clinical-stage biotechnology company focused on metabolic and infectious diseases. Develops novel oral small-molecule GLP-1 receptor agonists for obesity. Pursuing wholly owned global development strategy.
None